PCML
NVO

Pavaki Capital Management LLC’s Novo Nordisk NVO Stock Holding History

Pavaki Capital Management LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$509K – 159
2025
Q4 		$509K Buy
+10,000
New +$511K 0.2% 66

Other funds holding NVO

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
MG
Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Pavaki Capital Management LLC's NVO Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Novo Nordisk (NVO) position steady in Q2 2026 at 4,500 shares worth $216K. The position accounts for 0.08% of the portfolio, ranked #128.

Pavaki Capital Management LLC first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $229K in Q4 2025. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Pavaki Capital Management LLC held 4,500 shares of Novo Nordisk worth $216K as of Q2 2026.
  • Pavaki Capital Management LLC left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.08% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #128 holding.
  • Pavaki Capital Management LLC first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management LLC's Novo Nordisk position peaked at $229K in Q4 2025.
  • 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.